T1	p 77 106	anemic patients with cancer .
T2	p 222 262	patients with cancer-associated anemia .
T3	p 284 338	Eligible patients were randomly assigned at enrollment
T4	p 571 725	Three hundred sixty-five patients were enrolled . One hundred eighty-three patients were assigned to the 40K arm , and 182 were assigned to the 120K arm .
T5	i 59 73	erythropoietin
T6	i 138 150	epoetin alfa
T7	i 205 217	epoetin alfa
T8	i 350 408	three weekly doses of epoetin alfa 40,000 U subcutaneously
T9	i 453 465	epoetin alfa
T10	i 494 506	epoetin alfa
T11	i 1544 1556	epoetin alfa
T12	i 1751 1765	epoetin alfa .
T13	o 757 802	proportion of patients requiring transfusions
T14	o 1062 1089	hemoglobin ( Hb ) increment
T15	o 1119 1133	drug dose held
T16	o 1145 1152	high Hb
T17	o 1170 1210	mean end-of-study Hb levels . Toxicities
T18	o 1223 1238	thromboembolism
T19	o 1245 1261	overall survival
T20	o 1314 1344	global quality of life ( QOL )
T21	o 1426 1448	global QOL improvement
T22	o 1471 1487	end-of-study QOL
T23	o 1653 1670	transfusion needs
T24	o 1686 1691	QOL .
T25	o 1696 1708	Hb increment